CRSP insider buying and SEC filings, explained
CRISPR Therapeutics AG · CIK 1674416
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- V8
- Fiscal year end
- Dec 31
- Former names
- CRISPR Therapeutics AG
Insider activity in the last 12 months
Bought
$50K
Insiders who bought
1
Sold (not marked 10b5-1)
$6.1M
Planned sales (10b5-1)
$11.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 19, 2026 | Sale | Samarth Kulkarni (CEO and Director) sold 47,837 shares at $49.78 ($2.4M). Holdings down 13% to 311,899 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 20, 2026, 5:35 PM ET |
| Oct 14, 2026 | Planned (10b5-1) | Simeon George (Director) sold 14,514 shares at about $49.63 ($720K), marked as a 10b5-1 plan trade. Holdings down 48% to 15,486 shares. | SEC filing Filed Oct 16, 2026, 5:45 PM ET |
| Oct 14, 2026 | Sale | James R. Kasinger (General Counsel and Secretary) sold 1,040 shares at $49.26 ($51K). Holdings down 1% to 95,857 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 15, 2026, 5:35 PM ET |
| Oct 14, 2026 | Sale | Samarth Kulkarni (CEO and Director) sold 4,098 shares at $49.26 ($202K). Holdings down 2% to 259,736 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 15, 2026, 5:35 PM ET |
| Oct 6, 2026 | Planned (10b5-1) | James R. Kasinger (General Counsel and Secretary) sold 1,990 shares at about $60.04 ($119K), marked as a 10b5-1 plan trade. Holdings down 2% to 94,784 shares. | SEC filing Filed Oct 8, 2026, 5:35 PM ET |
| Sep 22, 2026 | Planned (10b5-1) | James R. Kasinger (General Counsel and Secretary) sold 10,400 shares at about $60.24 ($626K), marked as a 10b5-1 plan trade. Holdings down 10% to 94,784 shares. | SEC filing Filed Sep 24, 2026 |
| May 29, 2026 | Sale | Naimish Patel (Chief Medical Officer) sold 3,786 shares at $55.62 ($211K). Holdings down 16% to 19,357 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 1, 2026 |
| Mar 23, 2026 | Sale | James R. Kasinger (General Counsel and Secretary) sold 3,182 shares at $46.78 ($149K). Holdings down 3% to 94,308 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 24, 2026 |
| Mar 23, 2026 | Sale | Samarth Kulkarni (CEO and Director) sold 10,020 shares at $46.78 ($469K). Holdings down 4% to 255,501 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 24, 2026 |
| Mar 23, 2026 | Sale | Raju Prasad (CFO) sold 3,708 shares at $46.78 ($173K). Holdings down 19% to 15,565 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 24, 2026 |
| Mar 16, 2026 | Sale | Naimish Patel (Chief Medical Officer) sold 3,150 shares at $48.26 ($152K). Holdings down 19% to 13,143 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Raju Prasad (CFO) sold 9,869 shares at $48.26 ($476K). Holdings down 42% to 13,773 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | James R. Kasinger (General Counsel and Secretary) sold 3,450 shares at $48.26 ($166K). Holdings down 4% to 91,240 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Samarth Kulkarni (CEO and Director) sold 10,349 shares at $48.26 ($499K). Holdings down 4% to 245,834 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 11, 2026 | Sale | James R. Kasinger (General Counsel and Secretary) sold 2,800 shares at $52.80 ($148K). Holdings down 3% to 87,815 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 12, 2026 |
| Mar 11, 2026 | Sale | Samarth Kulkarni (CEO and Director) sold 9,798 shares at $52.80 ($517K). Holdings down 4% to 235,558 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 12, 2026 |
| Feb 19, 2026 | Sale | Samarth Kulkarni (CEO and Director) sold 6,967 shares at $52.58 ($366K). Holdings down 3% to 226,106 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
| Feb 19, 2026 | Sale | James R. Kasinger (General Counsel and Secretary) sold 2,112 shares at $52.58 ($111K). Holdings down 2% to 85,115 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
| Apr 3, 2025 | Purchase (code P) | Naimish Patel (Chief Medical Officer) bought 1,508 shares at $32.96 ($50K), reported as a purchase (code P). New position of 1,508 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 22, 2026 | Planned (10b5-1) | Raju Prasad (CFO) sold 34,972 shares at about $60.19 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 84% to 6,767 shares. | SEC filing Filed Jan 26, 2026 |
| Jan 20–22, 2026 | Planned (10b5-1) | Samarth Kulkarni (CEO and Director) sold 90,000 shares between Jan 20 and Jan 22 at about $57.40 ($5.2M), marked as a 10b5-1 plan trade. Holdings down 40% to 134,201 shares. | SEC filing Filed Jan 22, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Raju Prasad (CFO) sold 29,700 shares at about $60.16 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 81% to 6,767 shares. | SEC filing Filed Jan 8, 2026 |
| Dec 22, 2025 | Planned (10b5-1) | Raju Prasad (CFO) sold 10,000 shares at about $55.95 ($560K), marked as a 10b5-1 plan trade. Holdings down 60% to 6,767 shares. | SEC filing Filed Dec 23, 2025 |
44 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 4:07 PM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow CRSP in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.